糠酸氟替卡松／维兰特罗治疗慢性阻塞性肺疾病的有效性与安全性  

Effectiveness and safety of fluticasone furoate/vilanterol versus for the treatment of chronic obstructive pulmonary disease

作　　者：陈健聪 吴锡平[2] Chen Jiancong;Wu Xiping(Department of Respiratory Medicine, the Second Clinical Medical College of Southern Medical University, Guangzhou 510280, China)

机构地区：[1]南方医科大学第二临床医学院,广州510280 [2]南方医科大学珠江医院呼吸内科,广州510280

出　　处：《国际呼吸杂志》2018年第7期549-553,共5页International Journal of Respiration

摘　　要：糠酸氟替卡松/维兰特罗 （FF/VI）复方干粉吸入剂是2013年FDA批准上市,用于治疗慢性阻塞性肺疾病 （COPD）的一种吸入剂糖皮质激素/长效β2 激动剂。目前,其有效性主要包括改善COPD患者的症状、肺功能和生活质量,同时能降低急性加重的风险。此外,其安全性也引起广泛关注。现将FF/VI对COPD的有效性和安全性进行综述。Fluticasone furoate/vilanterol versus （FF/VI） is a fixed combination inhalation powder comprising an inhaled corticosteroid and long-acting beta2-agonist （ICS/LABA） approved for the treatment of chronic obstructive pulmonary disease （COPD） by FDA in 2013. At present, its effectiveness included improving the symptoms of COPD, lung function, quality of life and reducing the risk of acute exacerbation. Besides, its safety also arouses wide public concern. Now, effectiveness and safety of FF/VI for the treatment of COPD are reviewed.

关 键 词：糠酸氟替卡松/维兰特罗 慢性阻塞性肺疾病 有效性 安全性 

分 类 号：R563.9[医药卫生—呼吸系统]